Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-01
2005-02-01
McKenzie, Thomas (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S357000, C514S359000, C514S383000, C514S539000, C514S563000, C514S603000, C514S617000, C514S618000, C514S619000, C514S674000, C514S764000, C546S300000, C546S337000, C548S255000, C548S267600, C558S415000, C560S017000, C560S041000, C562S449000, C562S450000
Reexamination Certificate
active
06849648
ABSTRACT:
A compound of Formula Ior a pharmaceutically acceptable salt thereof, or a tautomer thereof, wherein G1, G2, and B are as defined in the application, are selective inhibitors of MMP-13. The compounds are useful for treating diseases mediated by MMP-13, including cancer and arthritis.
REFERENCES:
patent: 3655679 (1972-04-01), Shen et al.
patent: 4412856 (1983-11-01), Brunner et al.
patent: 4818819 (1989-04-01), Taylor et al.
patent: 4902796 (1990-02-01), Taylor et al.
patent: 5389631 (1995-02-01), Claremon et al.
patent: 5646141 (1997-07-01), Varney et al.
patent: 5929097 (1999-07-01), Levin et al.
patent: 5948780 (1999-09-01), Peterson, Jr. et al.
patent: 5990116 (1999-11-01), Nussbaumer
patent: 6008243 (1999-12-01), Bender et al.
patent: 6225311 (2001-05-01), Levin et al.
patent: 20020151555 (2002-10-01), Barvian et al.
patent: 20020151558 (2002-10-01), Andrianjara et al.
patent: 20020156061 (2002-10-01), Barvian et al.
patent: 20020156069 (2002-10-01), Picard et al.
patent: 20020161000 (2002-10-01), Barvian et al.
patent: 20020193377 (2002-12-01), Andrianjara et al.
patent: 20030004172 (2003-01-01), Harter et al.
patent: 20030130278 (2003-07-01), Gaudilliere et al.
patent: 20040043979 (2004-03-01), Picard
patent: 20040048863 (2004-03-01), Bunker et al.
patent: 20040053952 (2004-03-01), Hicks et al.
patent: 20040063673 (2004-04-01), Johnson
patent: 0418797 (1994-08-01), None
patent: 0463592 (1994-08-01), None
patent: 0935963 (1999-08-01), None
patent: 1138680 (2001-10-01), None
patent: 8-143568 (1996-06-01), None
patent: 10195063 (1998-07-01), None
patent: WO 9616046 (1996-05-01), None
patent: 9616046 (1996-05-01), None
patent: WO 9633181 (1996-10-01), None
patent: WO 9703967 (1997-02-01), None
patent: 9816514 (1998-04-01), None
patent: WO 9902497 (1999-01-01), None
patent: WO 0009485 (2000-02-01), None
patent: WO 2000007999 (2000-02-01), None
patent: 0035906 (2000-06-01), None
patent: 0040561 (2000-07-01), None
patent: 0045063 (2000-08-01), None
patent: WO 0112611 (2001-02-01), None
patent: WO 2001053274 (2001-07-01), None
patent: 0155133 (2001-08-01), None
patent: 0163244 (2001-08-01), None
patent: 0206513 (2002-01-01), None
patent: WO 0234726 (2002-05-01), None
patent: WO 0234753 (2002-05-01), None
patent: 02064080 (2002-08-01), None
patent: 02064547 (2002-08-01), None
patent: 02064568 (2002-08-01), None
patent: 02064571 (2002-08-01), None
patent: 02064572 (2002-08-01), None
patent: 02064578 (2002-08-01), None
patent: 02064595 (2002-08-01), None
patent: 02064598 (2002-08-01), None
patent: 02064599 (2002-08-01), None
patent: WO 2003033478 (2003-04-01), None
patent: WO03049738 (2003-06-01), None
patent: WO 2004014366 (2004-02-01), None
patent: WO 2004014384 (2004-02-01), None
patent: WO 2004014868 (2004-02-01), None
patent: WO 2004014892 (2004-02-01), None
Watanabe, Shin-Ichi; Yamamoto, Keiichirou; Itagaki, Yukiko; Iwamura, Tatsunori; Iwama, Tetsuo; Kataoka, Tadashi, Tetrahedron, 56(6), 855-863 (English) 2000.*
Shen, Dong; Diele, Siegmar; Pelzl, Gerhard; Wirth, Ina; Tschierske, Carsten, Journal of Materials Chemistry, 9(3), 661-672 (English) 1999.*
Whittaker, Mark et al, Celltransmissions, vol. 17, No. 1, 2001, pp. 3-14.*
Aldrich Chemical Company, Milwaukee, WI, 1992, p. 989, entry 11,770-6.*
van den Berg WB, Lessons from animal models of osteoarthritis, Curr Opin Rheumatol Sep. 2001;13(5):452-6, (abstract) Medline [online].Bethesda, MD, USA: United States National Library of Medicine, [retrieved on May 21, 2003]..*
Pendas AM, An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies, Clin Chim Acta Feb. 15, 2000;291(2):137-55, (abstract) Medline [online]. NLM [retrieved on May 21, 2003]..*
Draetta, G. and Pagano, M. in “Annual Reports in Medicinal Chemistry, vol. 31”, 1996, Academic Press, San Diego, p 241-246.*
Polman, C.H. et al, BMJ 2000, 321, 490-4.*
Cohen, J.A. et al, J. Neuroimmun., 1999, 98 29-36.*
John Montana & Andrew Baxter, “The design of selective non-substrate-based matrix metalloproteinase inhibitors”, Current Opinion in Drug Discovery & Development 2000, 3(4):353-361.
Clark et al., “Matrix metalloproteinase inhibitors in the treatment of arthritis”, Current Opinion in Anti-inflammatory & Immunomodulatory Investigational Drugs 2000, 2(1):16-25.
Chen et al., “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design”, J. Am. Chem. Soc. 2000, 122-9648-9654.
M.G. Natchus, et al., “Development of New Carboxylic Acid-Based MMP Inhibitors Derived from Functionalized Propargylglycines”, Journal of Medicinal Chemistry 2001, 44(7):1060-1071, Derwent Publication Lt. Abstract No. 2001-514548; XP002213435.
A.B. Dyatkin et al., “The Solid Phase Synthesis of Complex Propargylamines Using the Combination of Sonogashira and Mannich Reactions”, Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, NL 1998, 39(22)3647-3650.
E.C. Taylor, et al., “Pteridines. 51. A New and Unequivocal Route to C-6 Carbon-Substituted Pterins and Pteridines”, J. Org. Chem. 1987, 52:3997-4000.
E.C. Taylor, et al., “Convergent and Efficient Palladium-Effected Synthesis of 5,10-Dideaza-5,6,7,8-tetrahydrofolic Acid (DDA THF)”, J. Org. Chem. 1989, 52:3618-3624.
Freije, Jose M., et al, “Molecular Cloning and Expression of Collagenase-3, a Novel Human Matrix Metalloproteinase Produced by Breast Carcinomas”, The Jouranl of Biological Chemistry, 1994; 269(24): pp 16766-16773.
Mitchell, Peter G., et al, “Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage”, J. Clin. Invest. 1996; 97(3): pp 761-768.
Beckett, R. Paul, et al, “Matrix Metalloproteinase Inhibitors 1998”, Exp. Opin. Ther. Patents, 1998; 8(3): pp 259-260.
U.S. Appl. No. 10/071,032, filed Feb. 8, 2002, Dyer et al.
Lisa A. Neuhold, et al., “Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice”, J. Clin. Invest.., vol. 107, No. 1, Jan. 2001, pp 35-44.
Leif Dahlberg, et al., “Selective Enhancement of Collagenase-mediated Cleavage of Resident Type II Collagen In Cultured Osteoarthritic Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase 1 (Matrix Metalloproteinase 1)”. Arthritis & Rheumatism, vol. 43, No. 3, Mar. 2000, pp 673-682.
R. Clark Billinghurst, et al., “Comparison of the degradation of type II collagen and Proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage of collagenase”, Arthritis & Rheumatism, vol. 43, No. 3, Mar. 2000, pp 664-672.
Peter G. Mitchell, et al., “Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage”, J. Clin. Invest., vol. 97, No. 3, Feb. 1996, pp 761-768.
R. Clark Billinghurst, et al., “Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage”, J. Clin. Invest., vol. 97, No. 7, Apr. 1997, pp 1534-1545.
Kosaku Hirota, et al. “Novel Synthesis of Pyrido[3,4-d]Pyrimidines, Pyrido[2,3-d]-Pyrimidines, and Quinazolines via Palladium-Catalyzed Oxidative Coupling”, Heterocycles, vol. 37, No. 1, 1994, pp 563-570.
Bunker Amy Mae
Harter William Glen
Hicks James Lester
O'Brien Patrick Michael
Pham Ly
McKenzie Thomas
Pfizer Inc.
Purchase, Jr. Claude F.
Warner-Lambert & Company
LandOfFree
Phenylene alkyne matrix metalloproteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenylene alkyne matrix metalloproteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylene alkyne matrix metalloproteinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3504648